CYDY News and Press, CytoDyn Inc From 01/29/24

2024-01-29 08:50:04 ET More on CytoDyn Financial information for CytoDyn Read the full article on Seeking Alpha For further details see: CytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFO

VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob Lalezari, formerly interim...

Cytodyn Inc (CYDY) is expected to report for Q2 2024 SeaChange International Inc. (SEAC) is expected to report for quarter end 2023-10-31 United Microelectronics Corporation (NEW) (UMC) is expected to report $0.15 for Q4 2023 Safestore Hldgs Plc (SFSHF) is expected to report for Q4 20...

SeaChange International Inc. (SEAC) is expected to report for quarter end 2023-10-31 Helen of Troy Limited (HELE) is expected to report $2.46 for Q3 2024 Commercial Metals Company (CMC) is expected to report $1.43 for Q1 2024 Pure Cycle Corporation (PCYO) is expected to report for Q1 ...

VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief...

2023-11-21 09:22:34 ET More on CytoDyn Financial information for CytoDyn For further details see: CytoDyn appoints Lalezari as its interim CEO

VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as ...

VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company. Throughout our history, CytoDyn has made great st...

Equity Bancshares Inc. Class A (EQBK) is expected to report $0.75 for Q3 2023 Silvergate Capital Corporation Class A (SICP) is expected to report for Q3 2023 Bellway plc ADR (BLWYY) is expected to report for Q4 2023 Fulton Financial Corporation (FULT) is expected to report $0.4 for Q3...

North Dallas Bank & Trust Co. (NODB) is expected to report for Q3 2023 Neogen Corporation (NEOG) is expected to report $0.14 for Q1 2024 E2open Parent Holdings Inc.Class A (ETWO) is expected to report $0.04 for Q2 2024 TSR Inc. (TSRI) is expected to report for Q1 2024 Solitron...